Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation

Journal of Cardiology

Volumn 69, Issue 1, 2017, Pages 228-235

  Yoshimura, Akino ^a   Iriki, Yasuhisa ^a   Ichiki, Hitoshi ^a   Oketani, Naoya ^a   Okui, Hideki ^a   Maenosono, Ryuichi ^a   Namino, Fuminori ^a   Miyata, Masaaki ^a   Ohishi, Mitsuru ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Ablation; Anticoagulant; Atrial fibrillation; Complication

Indexed keywords

APIXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CATHETER ABLATION; CEREBRAL MICROTHROMBOEMBOLISM; CHADS2 SCORE; CORONARY ANGIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOPERICARDIUM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED; CONTROLLED STUDY; INTRACRANIAL THROMBOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERICARDIAL EFFUSION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REGISTER;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; FACTOR XA INHIBITORS; FEMALE; HUMANS; INCIDENCE; INTRACRANIAL THROMBOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; REGISTRIES; RIVAROXABAN; WARFARIN;

EID: 84964681278     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.03.014     Document Type: Article

References (50)

1. [1] Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22 (1991), 983–988.
2. [2] Wolf, P.A., Dawber, T.R., Thomas, H.E. Jr., Kannel, W.B., Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 28 (1978), 973–977.
3. [3] Schnabel, R.B., Sullivan, L.M., Levy, D., Pencina, M.D., Massaro, J.M., D'Agostino, R.B. Sr., Newton-Cheh, C., Yamamoto, J.F., Magnani, J.W., Tadros, T.M., Kannel, W.B., Wang, T.J., Ellinor, P.T., Wolf, P.A., Vasan, R.S., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009), 739–745.
4. [4] Krahn, A.D., Manfreda, J., Tate, R.B., Mathewson, F.A., Cuddy, T.E., The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98 (1995), 476–484.
5. [5] Levy, S., Maarek, M., Coumel, P., Guize, L., Lekieffre, J., Medvedowsky, J.L., Sbaoun, A., Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 15 (1999), 3028–3035.
6. [6] Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
7. [7] Lip, G.Y., Frison, L., Halperin, J.L., Lane, D.A., Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41 (2010), 2731–2738.
8. [8] Piccini, J.P., Singer, D.E., Putting risk prediction in atrial fibrillation into perspective. Eur Heart J 33 (2012), 1431–1433.
9. [9] Singer, D.E., Chang, Y., Fang, M.C., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., Go, A.S., The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 151 (2009), 297–305.
10. [10] Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
11. [11] Di Biase, L., Burkhardt, J.D., Santangeli, P., Mohanty, P., Sanchez, J.E., Horton, R., Gallinghouse, G.J., Themistoclakis, S., Rossillo, A., Lakkireddy, D., Reddy, M., Hao, S., Hongo, R., Beheiry, S., Zagrodzky, J., et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 129 (2014), 2638–2644.
12. [12] Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
13. [13] Patel, M.R., Mahaffey, K.W., Gang, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., Fox, K.A., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
14. [14] Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaaker, G., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
15. [15] Haissaguerre, M., Jais, P., Shah, D.C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Le Mouroux, A., Le Metayer, P., Clementy, J., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 (1998), 659–666.
16. [16] Wazni, O.M., Marrouche, N.F., Martin, D.O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., Gutleben, K., Pisano, E., Potenza, D., Fanelli, R., Raviele, A., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293 (2005), 2634–2640.
17. [17] Pappone, C., Rosanio, S., Augello, G., Gallus, G., Vicedomini, G., Mazzone, P., Gulletta, S., Gugliotta, F., Pappone, A., Santinelli, V., Tortoriello, V., Sala, S., Zangrillo, A., Crescenzi, G., Benussi, S., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 (2003), 185–197.
18. [18] Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.H., Klein, G., Packer, D., Skanes, A., Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111 (2005), 1100–1105.
19. [19] Stabile, G., Bertaglia, E., Senatore, G., De Simone, A., Zoppo, F., Donnici, G., Turco, P., Pascotto, P., Fazzari, M., Vitale, D.F., Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 27 (2006), 216–221.
20. [20] Oral, H., Chugh, A., Good, E., Wimmer, A., Dey, S., Gadeela, N., Sankaran, S., Crawford, T., Sarrazin, J.F., Kuhne, M., Chalfoun, N., Wells, D., Frederick, M., Fortino, J., Benloucif-Moore, S., et al. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation 115 (2007), 2606–2612.
21. [21] Nademanee, K., McKenzie, J., Kosar, E., Schwab, M., Sunsaneewitayakul, B., Vasavakul, T., Khunnawat, C., Ngarmukos, T., A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 43 (2004), 2044–2053.
22. [22] Nault, I., Miyazaki, S., Forclaz, A., Wright, M., Jadidi, A., Jais, P., Hocini, M., Haissaguerre, M., Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. Eur Heart J 31 (2010), 1046–1054.
23. [23] Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.H., Klein, G., Natale, A., Packer, D., Skanes, A., Ambrogi, F., Biganzoli, E., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
24. [24] Kanagaratnam, L., Tomassoni, G., Schweikert, R., Pavia, S., Bash, D., Beheiry, S., Lesh, M., Niebauer, M., Saliba, W., Chung, M., Tchou, P., Natale, A., Empirical pulmonary vein isolation in patients with chronic atrial fibrillation using a three-dimensional nonfluoroscopic mapping system: long-term follow-up. Pacing Clin Electrophysiol 24 (2001), 1774–1779.
25. [25] Oral, H., Knight, B.P., Tada, H., Ozaydin, M., Chugh, A., Hassan, S., Scharf, C., Lai, S.W., Greenstein, R., Pelosi, F. Jr., Strickberger, S.A., Morady, F., Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 105 (2002), 1077–1081.
26. [26] Willems, S., Klemm, H., Rostock, T., Brandstrup, B., Ventura, R., Steven, D., Risius, T., Lutomsky, B., Meinertz, T., Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J 27 (2006), 2871–2878.
27. [27] Nademanee, K., Schwab, M.C., Kosar, E.M., Karwecki, M., Moran, M.D., Visessook, N., Michael, A.D., Ngarmukos, T., Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 51 (2008), 843–849.
28. [28] Nademanee, K., Lockwood, E., Oketani, N., Gidney, B., Catheter ablation of atrial fibrillation guided by complex fractionated atrial electrogram mapping of atrial fibrillation substrate. J Cardiol 55 (2010), 1–12.
29. [29] Iriki, Y., Ishida, S., Oketani, N., Ichiki, H., Okui, H., Ninomiya, Y., Maenosono, R., Matsushita, T., Miyata, M., Hamasaki, S., Tei, C., Relationship between clinical outcomes and unintentional pulmonary vein isolation during substrate ablation of atrial fibrillation guided solely by complex fractionated atrial electrogram mapping. J Cardiol 58 (2011), 278–286.
30. [30] Yoshino, S., Yoshikawa, A., Hamasaki, S., Ishida, S., Oketani, N., Saihara, K., Okui, H., Kuwahata, S., Fujita, S., Ichiki, H., Ueya, N., Iriki, Y., Maenosono, R., Miyata, M., Tei, C., Atrial fibrillation-induced endothelial dysfunction improves after restoration of sinus rhythm. Int J Cardiol 168 (2013), 1280–1285.
31. [31] Estner, H.L., Hessling, G., Ndrepepa, G., Wu, J., Reents, T., Fichtner, S., Schmitt, C., Bary, C.V., Kolb, C., Karch, M., Zrenner, B., Deisenhofer, I., Electrogram-guided substrate ablation with or without pulmonary vein isolation in patients with persistent atrial fibrillation. Europace 10 (2008), 1281–1287.
32. [32] Gaita, F., Caponi, D., Pianelli, M., Scaglione, M., Toso, E., Cesarani, F., Boffano, C., Gandini, G., Valentini, M.C., De Ponti, R., Halimi, F., Leclercq, J.F., Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 122 (2010), 1667–1673.
33. [33] Scherr, D., Sharma, K., Dalal, D., Spragg, D., Chilukuri, K., Cheng, A., Dong, J., Henrikson, C.A., Nazarian, S., Berger, R.D., Calkins, H., Marine, J.E., Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009), 1357–1363.
34. [34] Schrickel, J.W., Lickfett, L., Lewalter, T., Mittman-Braun, E., Selbach, S., Strach, K., Nahle, C.P., Schwab, J.O., Linhart, M., Andrie, R., Nickenig, G., Sommer, T., Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 12 (2010), 52–57.
35. [35] Asirvatham, S.J., Friedman, P.A., Silent cerebral thromboembolism with left atrial ablation: a lurking danger. J Cardiovasc Electrophysiol 17 (2006), 8–10.
36. [36] Kok, L.C., Mangrum, J.M., Haines, D.E., Mounsey, J.P., Cerebrovascular complication associated with pulmonary vein ablation. J Cardiovasc Electrophysiol 13 (2002), 764–767.
37. [37] Ichiki, H., Oketani, N., Ishida, S., Iriki, Y., Okui, H., Maenosono, R., Ninomiya, Y., Matsushita, T., Miyata, M., Hamasaki, S., Tei, C., Incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation guided by complex fractionated atrial electrogram. J Cardiovasc Electrophysiol 23 (2012), 567–573.
38. [38] Di Biase, L., Burkhardt, J.D., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G.J., Lakkireddy, D., Verma, A., Khaykin, Y., Hongo, R., Hao, S., Beheiry, S., Pelargonio, G., Dello Russo, A., Casella, M., et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 121 (2010), 2550–2556.
39. [39] Vazquez, S.R., Johnson, S.A., Rondina, M.T., Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res 126 (2010), e69–e77.
40. [40] Hussein, A.A., Martin, D.O., Saliba, W., Patel, D., Karim, S., Batal, O., Banna, M., Williams-Andrews, M., Sherman, M., Kanj, M., Bhargava, M., Dresing, T., Callahan, T., Tchou, P., Di Biase, L., et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 6 (2009), 1425–1429.
41. [41] Wazni, O.M., Beheiry, S., Fahmy, T., Barrett, C., Hao, S., Patel, D., Di Biase, L., Martin, D.O., Kanj, M., Arruda, M., Cummings, J., Schweikert, R., Saliba, W., Natale, A., Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 116 (2007), 2531–2534.
42. [42] Ichiki, H., Oketani, N., Ishida, S., Iriki, Y., Okui, H., Maenosono, R., Namino, F., Ninomiya, Y., Miyata, M., Hamasaki, S., Tei, C., The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. Pacing Clin Electrophysiol 36 (2013), 1328–1335.
43. [43] Bassiouny, M., Saliba, W., Rickard, J., Shao, M., Sey, A., Diab, M., Martin, D.O., Hussein, A., Khoury, M., Abi-Saleh, B., Alam, S., Sengupta, J., Borek, P.P., Baranowski, B., Niebauer, M., et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 6 (2013), 460–466.
44. [44] Snipelisky, D., Kauffman, C., Prussak, K., Johns, G., Venkatachalam, K., Kusumoto, F., A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 35 (2012), 29–33.
45. [45] Providencia, R., Albenque, J.P., Combes, S., Bouzeman, A., Casteigt, B., Combes, N., Narayanan, K., Marijon, E., Boveda, S., Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 100 (2014), 324–335.
46. [46] Namino, F., Iriki, Y., Maenosono, R., Ichiki, H., Okui, H., Yoshimura, A., Oketani, N., Matsushita, M., Ohishi, M., Hashiguchi, T., The optimal setting of complex fractionated atrial electrogram software in substrate ablation for atrial fibrillation. J Arrhythmia 31 (2015), 6–11.
47. [47] Maenosono, R., Oketani, N., Ishida, S., Iriki, Y., Ichiki, H., Okui, H., Ninomiya, Y., Hamasaki, S., Namino, F., Matsushita, M., Tei, C., Hashiguchi, T., Effectiveness of esophagus detection by three-dimensional electroanatomical mapping to avoid esophageal injury during ablation of atrial fibrillation. J Cardiol 60 (2012), 119–125.
48. [48] Oketani, N., Ichiki, H., Iriki, Y., Okui, H., Maenosono, R., Namino, F., Ninomiya, Y., Ishida, S., Hamasaki, S., Tei, C., Catheter ablation of atrial fibrillation guided by complex fractionated atrial electrogram mapping with or without pulmonary vein isolation. J Arrhythmia 28 (2012), 311–323.
49. [49] Schellinger, P.D., Bryan, R.N., Caplan, L.R., Detre, J.A., Edelman, R.R., Jaigobin, C., Kidwell, C.S., Mohr, J.P., Sloan, M., Sorensen, A.G., Warach, S., Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 75 (2010), 177–185.
50. [50] Goya, M., Nogami, A., Hirao, K., Aonuma, K., Ablation perioperative dabigatran in use envisioning in Japan: The ABRIDGE-J Study Design. J Cardiol, 2015 http://dx.doi.org/10.1016/j.jjcc.2015.10.003.